Xiuning Le, Deputy Section Chief of Thoracic Medical Oncology at MD Anderson Cancer Center, shared a post by Federica Pecci et al. published in American Association for Cancer Research Journals on LinkedIn:
”Are we ready for ultra-precision oncology?
New online: First-line MET tyrosine kinase inhibitors versus immunotherapy ± chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLC, AACR Journals, Biagio Ricciuti, Federica Pecci, Alfredo Addeo, mdanderson DFCI.
- ~3,600 new METex14 lung cancer cases annually in the U.S. 🇺🇸
- For PD-L1 ≥80% (~1,400 pts): 1L immunotherapy improved both PFS and OS
- For PD-L1 <50% or pts with brain metastases (~1,800 pts): 1L targeted therapies (hashtag#tepotinib, capmatinib) delivered ORR, PFS, and OS benefit
- Many pts did not receive 2L+ therapies, even at major centers
This study highlights the future of ultra-precision oncology: tailoring treatment strategies not just by mutation driver MET, but by integrated clinicogenomic features in ever-smaller subsets of patients.”
Title: First-line MET tyrosine kinase inhibitors versus immunotherapy ± chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLC
Authors: Federica Pecci, Hui Li, Alessandro Di Federico, Jia Wu, Hong Chen, Eleonora Gariazzo, Francesco Mantuano, Edoardo Garbo, Mihaela Aldea, Valentina Santo, Don Gibbons, Hai Tran, Francesco Paoloni, Guilherme Rossato de Almeida, Giulio Metro, Andrea De Giglio, Francesco Gelsomino, Xinan Wang, Marcello Tiseo, Julia Rotow, Andrea Ardizzoni, J. Jack Lee, Mark M. Awad, Alfredo Addeo, Lingzhi Hong, Marcelo V. Negrao, Pasi A. Janne, John V. Heymach, Jianjun Zhang, Biagio Ricciuti, Xiuning Le
Read the Full Article.
More posts featuing Xiuning Le on OncoDaily.
